STAT-Diagnostica, a Barcelona, Spain-based medical diagnostics company, closed a €25m/28.5m Series C financing round.
The round was led by new investor Gilde Healthcare, with participation from existing investors Kurma Partners; Ysios Capital; Idinvest Partners; Boehringer Ingelheim Venture Fund; Caixa Capital Risc; and Axis.
The company intends to use the funds to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system.
Founded in 2010 by Jordi Carrera, CEO, STAT-Diagnostica is focused on the development of Near Patient Testing solutions where fast and accurate diagnostic results are needed. Its DiagCORE in vitro diagnostic system is a fully integrated molecular and immunoassay diagnostics system that performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48-multiplex capabilities via real-time PCR.
The company plans to target a range of decentralized testing environments with DiagCORE, including critical care and emergency medicine units within hospitals.
The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.